Biologics and biosimilars: what, why and how?
Year: 2017
Type: article
Abstract: Pharmaceutical products are doctors’ major armamentaria for preventing, curing, controlling or modifying disease processes in order to reduce hospitalisations, disabilities and premature death.1 Increasing knowledge of human diseases, especially after the decoding of the human genome, has accelerated the discovery of disease-related chemicals and/or proteins. These targets form the basis for the design of pharmaceutical compounds to alter biological activities and clinical outcomes. In 1982, the US Food and Drug Administration (FDA) approved human insulin (Humulin) as the first DNA-recombinant protein.
Source: ESMO Open
Authors: Juliana C.N. Chan, Anthony T.C. Chan
Institutions: Chinese University of Hong Kong, Prince of Wales Hospital
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W2600821126